Product news from the 11/04/05 News Brief

Share this article:

Novartis announced the FDA's approval of Exjade (deferasirox), a once-daily oral iron chelator designed to treat chronic iron overload due to blood transfusions in adults and children ages two and older.

Roche's Tarceva (erlotinib), has won FDA approval for treatment of advanced pancreatic cancer.

Savient Pharmaceuticals announced the FDA approval of its New Drug Application for Soltamox (tamoxifen oral solution) for the treatment of breast cancer in adjuvant and metastatic settings and to reduce risks of breast cancer in women with ductal carcinoma in situ (DCIS) and reduction of breast cancer incidence in women with high risk of breast cancer. Soltamox is the product of Savient's wholly owned subsidiary, Rosemont Pharmaceuticals Ltd., located in the U.K.

GlaxoSmithKline announced that the FDA has approved Arranon (nelarabine) Injection, a chemotherapy agent for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and Tcell lymphoblastic lymphoma (TLBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.